周报：CXO板块涨幅居前，中国创新药co-development出海提速-20251027

Investment Rating - The report assigns an "Outperform" rating to multiple companies in the healthcare sector, including BeiGene, WuXi AppTec, and Innovent Biologics, among others. A "Neutral" rating is given to Sinopharm Group [1]. Core Insights - The CXO sector has shown strong growth, with a 5.2% increase, while the innovative drug sector has been relatively weak, declining by 3.4% [5][30]. - The Hang Seng Healthcare Index has increased by 73.4% year-to-date, outperforming the Hang Seng Index by 43.3 percentage points [4][29]. - Recent strategic partnerships, such as the one between Innovent Biologics and Takeda, highlight the growing international competitiveness of Chinese pharmaceutical companies [6][31]. Summary by Sections Market Performance - The Hang Seng Healthcare Index fell by 0.8% during the week of October 20-24, 2025, underperforming the Hang Seng Index by 4.5 percentage points [4][29]. - The top-performing sectors included CXO/Research Services (+5.2%) and Pharmaceutical Distribution (+4.2%), while Biotech and Pharma sectors saw declines of 3.1% and 3.4%, respectively [5][30]. Strategic Developments - Innovent Biologics and Takeda reached a global strategic cooperation agreement worth $11.4 billion, marking a significant milestone in the international collaboration of Chinese pharmaceutical companies [10][31]. - Gushengtang announced a partnership with the Singaporean digital healthcare platform 1doc to introduce traditional Chinese medicine services in Singapore [15][35]. Future Outlook - The report emphasizes the importance of tracking the trend of "quality and quantity improvement" in the overseas expansion of Chinese innovative drugs, indicating a positive outlook for co-development initiatives [6][31]. - The medical service sector is currently at a valuation bottom, with expectations for improvement as domestic demand signals strengthen [7][32].